
89bio Inc (ETNB) Stock Forecast & Price Target
89bio Inc (ETNB) Analyst Ratings
Bulls say
89bio Inc., a clinical-stage biopharmaceutical company, is advancing its lead product candidate, pegozafermin, targeted at addressing critical liver and cardio-metabolic diseases, specifically nonalcoholic steatohepatitis and severe hypertriglyceridemia. The ongoing clinical trials for pegozafermin are generating positive preliminary results that suggest significant efficacy, thereby enhancing the company's prospects for future commercialization. Additionally, robust liquidity positions and strategic partnerships may support the continuation of its development pipeline, bolstering investor confidence in the company's long-term growth potential.
Bears say
89bio Inc faces significant risks that negatively impact its investment outlook, particularly related to the commercial potential of its product candidate, pegozafermin. Key concerns include the possibility of failing to meet peak revenue estimates due to limitations in market size, penetration, and pricing strategies, which could hinder the company's financial performance. Additionally, the inability to secure adequate capital resources for ongoing operations and development raises further fears about the viability of its commercialization efforts.
This aggregate rating is based on analysts' research of 89bio Inc and is not a guaranteed prediction by Public.com or investment advice.
89bio Inc (ETNB) Analyst Forecast & Price Prediction
Start investing in 89bio Inc (ETNB)
Order type
Buy in
Order amount
Est. shares
0 shares